Richter acquired the newly issued shares in a private placement for EUR 82.84 mln, paying the weighted average share price over the past 30 trading days. The lock-up period for the shares is 180 days.
The fresh capital will be used for the further development of biosimilars in the pipeline.
Richter CEO Gábor Orbán said the capital raise served to reinforce Richter's strategic partnership with Formycon.
"Joining forces in this way will provide scale benefits and new business opportunities for both parties, while ensuring mission critical knowledge and experience transfer in a fast-evolving industry," he added.
Formycon CEO Stefan Glombitza acknowledged Formycon's "very trustful and successful" operational cooperation with Richter over the past few years, using the company's manufacturing capacities.
"This transaction has the potential to generate strong momentum as it enables both parties to jointly leverage strategic long-term opportunities," he said.
Richter noted that global sales of biosimilars — follow-on versions of biopharmaceuticals, for which exclusivity has expired — could rise from more than USD 15 bln at present to over USD 74 bln by 2030.
Producing journalism that is worthy of the name is a costly business. For over 30 years, the publishers, editors and reporters of the Budapest Business Journal have striven to bring you business news that works, information that you can trust, that is factual, accurate and presented without fear or favor.Newspaper organizations across the globe have struggled to find a business model that allows them to continue to excel, without compromising their ability to perform. Most recently, some have experimented with the idea of involving their most important stakeholders, their readers.
We would like to offer that same opportunity to our readers. We would like to invite you to help us deliver the quality business journalism you require. Hit our Support the BBJ button and you can choose the how much and how often you send us your contributions.
